Articles from Liberate Bio, Inc.

Liberate Bio, Inc., a biotechnology company developing medicines which efficiently and selectively deliver payloads to immune cells while bypassing the live, announced an oral presentation by Melissa Deck - Director of Platform, demonstrating the success of Liberate’s RAPTOR™ screening platform and NHP data for the company’s first lead candidates at the Oligonucleotide and Peptide Therapeutics 2025 (TIDES) being held May 19th-22nd, 2025 in San Diego, California.

Liberate Bio, Inc., a company delivering genetic medicines that transcend liver-based limitations, announced an oral presentation demonstrating the success of their RAPTOR™ screening platform and its first generation of extrahepatic lipid nanoparticles at the Oligonucleotide and Peptide Therapeutics 2024 (TIDES) being held May 14-17, 2024, in Boston, Massachusetts.